event-trade登录编辑
RTTNews BiotechCodex · 实盘可交易 · 做多市场:美股▲ 赚 +11.68% · 已结算把握 5/10
北京时间·🕒 发布 10:47:22·⟳ 抓取 15:06:37 +4h19m·⚡ 决策 09-04 16:14:32 +1h07m·53.1 天前

Pro-Dex四季度业绩强劲增长,Modular Medical获Pivot软件增强FDA批准但已在前一交易日传播

在该汇总新闻中,只有Pro-Dex的盘后业绩公告具备新鲜、直接、可交易的公司级增量;其他候选要么已在盘前传播、要么无经营增量或仍是未来事件。

📄 原文RTTNews Biotech↗ 原文
6 Biotech Stocks In Focus: Modular Medical, Galmed, Pro-Dex, Connect Biopharma & More
Today's after-hours gainers include Modular Medical, following FDA clearance for a series of software enhancements to i…
ENTER▲ 做多Pro-DexPDEX.US🇺🇸小仓
▲ 赚 +11.68%入场 09-04 盘前首笔 @66.03 → 离场 09-08 常规开盘 @73.95
60.0070.0066.03做多 09-04离场 09-0808-1210-09
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(价格在入场线上方)、绿底 = 亏
💡 交易逻辑盘后业绩超强,前收+5%内低追
怎么买 限价买入 不高于昨收 +5%、仅下一个交易日,不成交作废
怎么卖 止盈 +6%(半仓)/+12%(清仓) · 止损 -5% · 时间止损 3日
不做 Modular Medical(MODD.US)
FDA软件增强批准方向正面,但首发在2026-09-03美股盘前,RTTNews盘后汇总已不是新增催化。
不做 Galmed Pharmaceuticals(GLMD.US)
股东大会事项缺少经营、资本结构或现金流的明确短线增量。
不做 eHealth(EHTH.US)
盘后上涨无特定新闻,且最近季度收入大幅下滑、亏损扩大,事件方向不足以做多。
不做 Connect Biopharma(CNTB.US)
会议参与和预计临床读出不是已发生的疗效或监管结果,且常规盘已大跌,需等真实数据。
不做 AVITA Medical(RCEL.US)
会议安排与既有季度表现不构成新的短线交易催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

分时走势

做多 PDEX.US Pro-Dex

建仓日早于近 30 天,只有日线图

成交明细 · 纸面

做多 PDEX.US Pro-Dex

收益状态+11.68% 已平仓
进场成交2026-09-04 · 盘前首笔 · 09-04 16:51 北京 · @66.0265 · 成交 2%
离场成交2026-09-08 · 常规开盘 · @73.95
毛收益+12.00%
成本+0.33%
净收益+11.68%
计入收益+0.18%
建仓日2026-09-04 · 进场不早于新闻时刻 + 2 分钟

收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-27 17:36

研究档案

结论摘要

Pro-Dex在美股收盘后发布2026财年四季度业绩,季度销售额同比增17%至2040万美元、EPS从0.36美元升至0.87美元,且增长来自最大客户下一代骨科手持设备放量;以约7464万美元TTM收入和约1.97亿美元市值看,单季利润改善对小市值公司有可见弹性。盘后已涨约8%至9%,因此不追高开,采用次日开盘限价买入;若跳空超过前收5%则放弃。

🔎 新鲜度:最早出现 2026-09-03 · 扩散 medium · price-in 风险 medium ↗ ↗ ↗

消息传播链

  1. 2026-09-03 16:11 EDT官方确认/否认SEC EDGAR原文 ↗
    Pro-Dex 8-K在2026-09-03 16:11:23 EDT被SEC接收,披露2026财年四季度和全年业绩。
  2. 2026-09-03官方确认/否认Pro-Dex业绩新闻稿/SEC附件99.1原文 ↗
    公司披露四季度净销售额2040万美元、同比增17%,净利润290万美元、EPS 0.87美元。
  3. 2026-09-04 02:47 UTC财经媒体扩散RTTNews Biotech非一手原文 ↗
    RTTNews盘后汇总多只医药股,称Pro-Dex受强劲季度业绩推动盘后上涨逾9%。
    市场反应:RTTNews称PDEX从61.75美元收盘价盘后升至67.50美元,涨9.31%。
  4. 2026-09-03 18:04 EDT市场反应StockAnalysis非一手原文 ↗
    行情聚合显示PDEX 2026-09-03收盘61.75美元,盘后约67.00美元,涨约8.5%。
    市场反应:盘后已部分重定价,需限制追高。

关键理由

  • Pro-Dex四季度净销售额2040万美元、同比增17%,EPS 0.87美元较去年0.36美元显著提升,显示最大客户下一代骨科手持设备放量正在转化为利润。
  • 公司TTM收入约7464万美元、TTM净利润约1200万美元,对约1.97亿美元市值而言,单季利润弹性足以影响短线重估。
  • 事件由SEC 8-K和公司业绩稿在2026-09-03收盘后披露,常规盘尚未消化,但盘后已有约8%至9%反应,需用限价控制追高。

主要风险

  • Pro-Dex backlog从去年同期5040万美元降至3290万美元,虽公司称主要是订单时点问题,但会削弱业绩延续性的确定性。
  • 盘后已经上涨约8%至9%,若次日开盘大幅高开,短线风险回报会快速恶化。

反向证据

  • 做多前查反向 · 来源 web · 日期 2026-09-03 · 影响 weakens
    2026财年10-K摘要显示Pro-Dex 2026-06-30 backlog为3290万美元,低于去年同期5040万美元,公司称主要由于订单时点,但仍是延续性风险。
    检索:Pro-Dex 2026 10-K backlog customer concentration risks largest customer handpiece 原文 ↗
  • 做多前查反向 · 来源 web · 日期 2026-09-03 · 影响 weakens
    盘后报价已较收盘上涨约8%至9%,若开盘继续高开,短线追高风险上升。
    检索:PDEX after hours price September 3 2026 Pro-Dex earnings 原文 ↗
  • 做多前查反向 · 来源 web · 日期 2026-09-04 · 影响 none
    RTTNews正文称EHTH盘后上涨无特定新闻,且最近季度收入同比下降45%、亏损扩大,不支持把异动扩展为做多候选。
    检索:eHealth Q2 2026 revenue down 45 net loss widened 原文 ↗

先例如何影响了这次决策

对本次决策的影响:先例不足使仓位从normal降至small,并把入场改为前收+5%以内限价,跳空过高则放弃。

方向:缺少已完成事件研究的同市场高相似样本,不能用历史胜率强行放大仓位;本次主要依据公司一手财务增量判断方向。

涨幅量级:没有足够高相似、锚点干净的医疗器械小盘股盘后业绩样本校准幅度,因此止盈设为保守的6%至12%。

形态:盘后已涨约8%至9%,存在次日高开后回落风险,但不是早于事件的price-in。

工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
  1. web_search 成功 ? · 0 ms
  2. web_search 成功 ? · 0 ms

原文全文

展开原文 · 6,384 字
Today's after-hours gainers include Modular Medical, following FDA clearance for a series of software enhancements to its Pivot tubeless patch pump; Galmed Pharmaceuticals, after shareholders approved all five proposals presented at its annual general meeting; and Pro-Dex, following the company's strong quarterly results, among others.
Read on…
Modular Medical Inc. (MODD), a commercial-stage medical device company, announced Thursday that it received FDA clearance for a series of software enhancements to its Pivot tubeless patch pump, a wearable insulin delivery system.
The latest clearance expands the functionality of the Pivot system, providing users with greater flexibility and customization in bolus dosing, an enhanced user interface (UI), and additional software upgrades designed to improve the overall user experience.
Modular Medical received FDA clearance for its next-generation Pivot tubeless insulin patch pump in April 2026. The company plans to begin the commercial launch of the product in October 2026 across five U.S. markets: Atlanta, Cincinnati/Lexington, Dallas, Houston, and Philadelphia.
MODD closed Thursday's trading at $3.42, down 1.16%. In after-hours, the stock was up 5.56% at $3.61.
Galmed Pharmaceuticals Ltd. (GLMD) said shareholders approved all five proposals presented at its annual general meeting on September 3, 2026.
The proposals included the re-election of two Class III directors, amendments to the company's Articles of Association to eliminate the par value of its ordinary shares and change the company's name to Eocene Ltd., approval of the company's Compensation Policy for Executive Officers and Directors, a 20% increase in director compensation, and the reappointment of Brightman Almagor Zohar & Co., a member firm of Deloitte Touche Tohmatsu Limited, as its independent registered public accounting firm.
GLMD closed Thursday's trading at $3.92, down 4.83%. In after-hours trading, the stock was up 9.69% at $4.30.
PRO-DEX INC. (PDEX) on Thursday announced financial results for its fiscal 2026 fourth quarter and full-year ended June 30, 2026, sending shares up over 9% in extended trading.
The company specializes in designing, developing, and manufacturing autoclavable, battery-powered and electric multi-function surgical drivers and shavers primarily used in orthopedic, thoracic, and craniomaxillofacial procedures.
Net sales for the three months ended June 30, 2026, increased 17% to $20.4 million from $17.5 million a year earlier, primarily due to higher revenue from the company's largest customer's next-generation orthopedic handpiece.
Net income increased to $2.9 million, or $0.87 per share, in the fiscal 2026 fourth quarter from $1.2 million, or $0.36 per share, in the same quarter of 2025.
PDEX closed Thursday's trading at $61.75, up 1.33%. In after-hours, the stock was up 9.31% at $67.50.
Shares of eHealth Inc. (EHTH) were up over 8% in after-hours trading on no specific news.
The company is a health insurance marketplace that uses technology and service platforms to help consumers research, compare, and enroll in health insurance plans. It offers its services online, by phone through licensed insurance agents, and through a combination of online and agent-assisted support.
For the second quarter ended June 30, 2026, the results of which were reported recently, net loss widened as revenues plunged nearly 45%.
Net loss attributable to common stockholders was $37.5 million, or $1.18 per share in Q2, 2026, compared with $29.8 million, or $0.98 per share, a year earlier. The total revenue for the second quarter of 2026 was $33.6 million, down 45% from $60.8 million in the year-ago quarter, primarily driven by lower Medicare enrollment volumes, and reduced marketing spending outside peak enrollment periods, among others.
EHTH closed Thursday's trading at $0.95, down 0.07%. In after-hours, the stock was up 8.41% at $1.03.
Connect Biopharma Holdings Limited (CNTB), a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory diseases, on Thursday, announced that its management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11:30 a.m. ET.
The company is also expected to report topline results this month from two Phase 2 Seabreeze trials: the Seabreeze STAT Asthma study and the Seabreeze STAT COPD study.The Seabreeze STAT Asthma study is evaluating Rademikibart in adolescents and adults with asthma and type 2 inflammation, while the Seabreeze STAT COPD study is evaluating the treatment in adults with COPD and type 2 inflammation.
CNTB closed Thursday's trading at $1.93, down 30.07%. In after-hours, the stock was up 3.11% at $1.99.
AVITA Medical Inc. (RCEL), a therapeutic acute wound care company, is scheduled to participate in two conferences this month.
The company will participate in the Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference on Thursday, September 10, 2026, followed by the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026, at 1:05 p.m. ET.
For the second quarter ended June 30, 2026, the company delivered strong results, with revenue increasing 18% year over year and 13% sequentially.
For full-year 2026, AVITA Medical expects net revenue to range between $86 million and $89 million, compared with $71.6 million in 2025. The company also expects to achieve cash flow breakeven in the fourth quarter of 2026.
RCEL closed Thursday's trading at $10.94, up 1.67%. In after-hours, the stock was down 0.18% at $10.92.
Did you know?
Scientists at the University of Nottingham have developed a bioinspired gel that could help repair damaged tooth enamel, strengthen healthy enamel, and potentially prevent future tooth decay. The gel mimics the natural process of enamel formation and could revolutionise tooth repair.
For comments and feedback contact: editorial@rttnews.com
Business News
August 28, 2026 14:11 ET Consumer prices data and economic output figures were the main news on the economics front in the U.S. this week. Similarly, latest data on demand for durable goods also drew attention. Survey data on the business morale in the biggest euro economy, Germany, were in focus in Europe. In Asia, the interest rate announcement from South Korea was the highlight.

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。